Colorectal Cancer News

New Phase II Study for Colon Cancer Patients Who Have Received Bevacizumab Now Recruiting

A new phase II study is recruiting patients with metastatic colon cancer who have received bevacizumab with chemotherapy.  Participants enrolled in this study will receive standard of care, or standard of care plus a mixture of irinotecan, cetuximab and ramucirumab. Ramucirumab, an anti-angiogenic agent that blocks the blood supply to a tumor, will be combined with an antibody that targets the epidermal growth factor receptor (EGFR) that is found on colorectal cancer cells. This study is sponsored by the Eastern Cooperative Oncology Group (ECOG) and is currently recruiting patients nationwide.

To learn if you are a match for this study, call the CCA’s Clinical Trial Matching Service at (866) 278-0392 to talk to a Clinical Trials Navigator.

Return